

# **Certificate of Analysis**

Print Date: May 24th 2024

www.tocris.com

**Product Name: DX3-213B** Catalog No.: 8070 Batch No.: 1

2749555-66-4 CAS Number:

**IUPAC Name:** (4,4-Difluoro-1-piperidinyl)[(3R)-1-[[4-[(1-methylethyl)sulfonyl]phenyl]sulfonyl]-3-piperidinyl]methanone

# 1. PHYSICAL AND CHEMICAL PROPERTIES

 $C_{20}H_{28}F_2N_2O_5S_2$ **Batch Molecular Formula:** 

**Batch Molecular Weight:** 478.57 **Physical Appearance:** White solid

DMSO to 50 mM Solubility: Store at -20°C Storage:

**Batch Molecular Structure:** 

# 2. ANALYTICAL DATA

**HPLC:** Shows 97.0% purity

**Chiral HPLC:** Shows 100.0% purity

<sup>1</sup>H NMR: Consistent with structure Mass Spectrum: Consistent with structure

Microanalysis:

Carbon Hydrogen Nitrogen

Theoretical 50.19 5.9 5.85 Found 50.26 5.95 5.71

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use



# **Product Information**

Print Date: May 24th 2024

www.tocris.com

Product Name: DX3-213B Catalog No.: 8070 1

CAS Number: 2749555-66-4

 $IUPAC\ Name: \ (4,4-Diffuoro-1-piperidinyl)[(3R)-1-[[4-[(1-methylethyl)sulfonyl]phenyl]sulfonyl]-3-piperidinyl]methanone$ 

### **Description:**

DX3-213B is a potent oxidative phosphorylation (OXPHOS) complex I (also known as NDUFS7) antagonist (IC $_{50}$  = 3.6 nM). DX3-213B impairs ATP generation (IC $_{50}$  = 11 nM) and inhibits the proliferation of MIA PaCa-2 cells (IC $_{50}$  = 9 nM) in galactose-containing media. In vivo, DX3-213B significantly delays tumor growth in a syngeneic mouse model of pancreatic cancer. DX3-213B is orally bioavailable.

#### **Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>20</sub>H<sub>28</sub>F<sub>2</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub>

Batch Molecular Weight: 478.57 Physical Appearance: White solid

**Minimum Purity:** ≥97%

#### **Batch Molecular Structure:**

Storage: Store at -20°C

# Solubility & Usage Info:

DMSO to 50 mM

#### Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. \*Unless contradicted by product-specific protocols or instructions, our standard recommendations apply:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

#### **Licensing Information:**

Sold under license from the University of Michigan

#### References:

Xu et al (2023) First-in-class NADH/Ubiquinone oxidoreductase core subunit S7 (NDUFS7) antagonist for the treatment of pancreatic cancer. ACS Pharmacol.Transl.Sci. 6 1164. PMID: 37588763.

**Xue** et al (2022) Multiparameter optimization of oxidative phosphorylation inhibitors for the treatment of pancreatic cancer. J.Med.Chem. **65** 3404. PMID: 35167303.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use